Britannia Bud Canada Holdings Inc. entered into a Letter of intent to acquire RISE Life Science Corp. (CNSX:RLSC) in a reverse merger transaction on January 21, 2021. Britannia Bud Canada Holdings Inc. entered into a definitive agreement to acquire RISE Life Science Corp. (CNSX:RLSC) in a reverse merger transaction on April 30, 2021. In connection with the Proposed Transaction, Britannia is currently closing a private round of financing of up to $5 million. In addition, the parties intend to complete a brokered offering of subscription receipts up to a total of $15 million at the time of the completion of the Proposed Transaction. Prior to or following the completion of the RTO Transaction the RISE Shares will be consolidated on the basis of one (1) post-Consolidation share for each 10 pre-Consolidation share, in exchange of their Britannia Shares, Britannia Shareholders will receive common shares in the capital of the RISE Shares at an exchange ratio of 120 RISE Shares for each one common share of Britannia. the Resulting Issuer's name will be "Britannia Life Sciences Inc.” The board of directors will be reconstituted to include Peter Shippen, Scott Secord, and Greg Taylor, Management of the resulting issuer is expected to be comprised of Peter Shippen (Chief Executive Officer), Boris Novansky (President), Sarah Zilik (Secretary and Chief Financial Officer) and Mark Bowes-Cavanagh (Chief Technical Officer). RISE and Britannia have mutually agreed to an appropriate break fee in the event either party elects to pursue an alternative transaction. The completion of the proposed transaction is subject to a number of conditions, including but not limited to the approval of the proposed transaction by the shareholders of RISE and Britannia, all required regulatory approvals, transaction is subject to acceptance by the Exchange including by the CSE and conversion of all outstanding RISE convertible debentures. RISE Board unanimously recommends that RISE Shareholders to vote in favor of transaction. On March 4, 2021, RISE Life completed a non-brokered private placement offering raising gross proceeds of $0.7 million. On April 15, 2021, RISE Life closed the final tranche of non-brokered private placement offering of subscription receipts for gross proceeds of $0.62 million. Shareholder meeting will be held on September 8, 2021. Bennett Jones LLP is legal counsel to Britannia and Irwin Lowy LLP is legal counsel to RISE. Blue Deer Capital Partners acted as financial advisor to Britannia in the transaction.

Britannia Bud Canada Holdings Inc. completed the acquisition of RISE Life Science Corp. (CNSX:RLSC) in a reverse merger transaction on November 12, 2021. Immediately prior to the effective time of amalgamation, the convertible debentures of Britannia Bud automatically converted to Britannia Bud shares at $1.55 per Britannia Bud share, and Britannia Bud shares issued pursuant to the conversion were exchanged alongside other Britannia Bud shares for BLAB shares in accordance with the terms. It is anticipated that the common shares of RISE will begin trading on the CSE by the end of this week under the symbol "BLAB". On October 26, 2021, RISE received conditional approval of the CSE to (i) list additional common shares of RISE, (ii) consolidate the RISE Shares on the basis of one post-consolidation RISE Share for each ten pre-consolidation RISE Shares, and (iii) change the name of RISE to Britannia Life Sciences Inc. RISE previously held its annual general and special meeting of shareholders on September 8, 2021, where the consolidation, name change and other corporate ancillary matters were overwhelmingly approved by shareholders of RISE.